Paula C. Eves

Paula C. Eves

Auto-generated profile, based on publicly available information

Paula C. Eves

Kroto Research Institute, Department of Engineering Materials, University of Sheffield, Broad Lane, Sheffield, United Kingdom

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1998 in Molecular Human Reproduction
Verified
Journal Article
Closed access
PDF file
RBRosamonde Banks
Rosamonde Banks
MFM. A. Forbes
M. A. Forbes
JSJ. Searles
J. Searles
DPD. Pappin
D. Pappin
BCB. Canas
B. Canas
PSP. J. Selby
P. J. Selby
Angiogenesis is essential in physiological processes including ovulation, implantation and pregnancy. One of the most potent regulators is the cytokine vascular endothelial growth factor (VEGF). We provide evidence for a novel pregnancy-associated soluble variant of the VEGF receptor Flt-1. VEGF ranged from undetectable to 157.3 pg/ml (mean 49.9 pg/ml, SD 48.4 pg/ml) in plasma samples from normal volunteers (n = 10), but was undetectable in plasma from pregnant women (n = 12) and amniotic fluid (n = 10). Recoveries of spiked VEGF were poor in pregnancy-related samples, indicating the presence of VEGF-binding activity which was confirmed using biosensor and chromatographic techniques. Partial purification and protein sequencing indicated a novel soluble form of Flt-1 with a subunit size of 150 kDa. Normally present as a multimeric structure of approximately 400-550 kDa, complexes of 600-700 kDa were formed following binding of multiple VEGF molecules. Reverse transcriptase polymerase chain reaction of Flt-1 in placenta, amnion, chorion, human umbilical vein endothelial cells and cord blood samples produced bands of the predicted sizes but failed to identify any additional RNA species, and possible reasons for this are discussed. Soluble Flt-1 may be important in regulating the actions of VEGF in angiogenesis and trophoblast invasion and may have therapeutic implications in diseases with inappropriate angiogenesis such as proliferative retinopathies and cancer.

1 February 2006 in Peptides
Verified
Journal Article
Closed access
PEPaula C. Eves
Paula C. Eves
SMSheila MacNeil
Sheila MacNeil
JHJohn W. Haycock
John W. Haycock

5 October 2005 in Plasma Processes and Polymers
Verified
Journal Article
Closed access
PDF file
ABAlison J. Beck
Alison J. Beck
JWJason D. Whittle
Jason D. Whittle
NBNial A. Bullett
Nial A. Bullett
PEPaula Eves
Paula Eves
SNSheila Mac Neil
Sheila Mac Neil
ASAlexander G. Shard
Alexander G. Shard

1 February 2000 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PEP. Eves
P. Eves
CLC. Layton
C. Layton
SHS. Hedley
S. Hedley
RDR.A. Dawson
R.A. Dawson
MWM. Wagner
M. Wagner
SNS. Mac Neil
S. Mac Neil

11 November 2003 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
PEP Eves
P Eves
JHJ Haycock
J Haycock
CLC Layton
C Layton
MWM Wagner
M Wagner
HKH Kemp
H Kemp
SNS Mac Neil
S Mac Neil
α-Melanocyte stimulating hormone (α-MSH) is known to have pleiotrophic functions including pigmentary, anti-inflammatory, antipyretic and immunoregulatory roles in the mammalian body. It is also reported to influence melanoma invasion with levels of α-, β- and γ-MSH correlated clinically with malignant melanoma development, but other studies suggest α-MSH acts to retard invasion. In the present study, we investigated the action of α-MSH on three human melanoma cell lines (HBL, A375-SM and C8161) differing in metastatic potential. α-melanocyte-simulating hormone reduced invasion through fibronectin and also through a human reconstructed skin composite model for the HBL line, and inhibited proinflammatory cytokine-stimulated activation of the NF-κB transcription factor. However, A375-SM and C8161 cells did not respond to α-MSH. Immunofluorescent microscopy and Western blotting identified melanocortin-1 receptor (MC-1R) expression for all three lines and MC-2R on HBL and A375-SM lines. Receptor binding identified a similar affinity for α-MSH for all three lines with the highest number of binding sites on HBL cells. Only the HBL melanoma line demonstrated a detectable cyclic adenosine monophosphate (cAMP) response to α-MSH, although all three lines responded to acute α-MSH addition (+(−)-N6-(2-phenylisopropyl)-adenosine (PIA)) with an elevation in intracellular calcium. The nonresponsive lines displayed MC-1R polymorphisms (C8161, Arg (wt) 151/Cys 151; A375-SM, homozygous Cys 151), whereas the HBL line was wild type. Stable transfection of the C8161 line with wild-type MC-1R produced cells whose invasion was significantly inhibited by α-MSH. From this data, we conclude that α-MSH can reduce melanoma cell invasion and protect cells against proinflammatory cytokine attack in cells with the wild-type receptor (HBL).

1 December 2003 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
PEPaula Eves
Paula Eves
EKEfthymia Katerinaki
Efthymia Katerinaki
CSClaire Simpson
Claire Simpson
CLChristopher Layton
Christopher Layton
RDRebecca Dawson
Rebecca Dawson
SNSheila Mac Neil
Sheila Mac Neil